Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.47)
# 215
Out of 5,180 analysts
130
Total ratings
52.54%
Success rate
20.19%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Reiterates: Buy | $38 → $58 | $42.81 | +35.48% | 10 | Mar 27, 2026 | |
| SRZN Surrozen | Reiterates: Buy | $32 → $36 | $28.44 | +26.58% | 4 | Mar 24, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $9.87 | +264.74% | 19 | Mar 20, 2026 | |
| ALDX Aldeyra Therapeutics | Downgrades: Neutral | $10 → $2 | $1.68 | +19.05% | 14 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $20.36 | +116.11% | 7 | Mar 17, 2026 | |
| IMUX Immunic | Maintains: Buy | $8 → $5 | $1.15 | +334.78% | 8 | Mar 2, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $100 → $80 | $1.33 | +5,915.04% | 9 | Feb 26, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $6.11 | +194.60% | 2 | Feb 20, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.41 | +325.53% | 4 | Feb 6, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $26.41 | +112.04% | 13 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $11.14 | +133.39% | 11 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $88 | $70.22 | +25.32% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $6.42 | +86.92% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $9.35 | +498.93% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.69 | +70.58% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 | $9.60 | -6.25% | 8 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $534.98 | -94.77% | 1 | Aug 22, 2023 |
Kodiak Sciences
Mar 27, 2026
Reiterates: Buy
Price Target: $38 → $58
Current: $42.81
Upside: +35.48%
Surrozen
Mar 24, 2026
Reiterates: Buy
Price Target: $32 → $36
Current: $28.44
Upside: +26.58%
4D Molecular Therapeutics
Mar 20, 2026
Reiterates: Buy
Price Target: $36
Current: $9.87
Upside: +264.74%
Aldeyra Therapeutics
Mar 18, 2026
Downgrades: Neutral
Price Target: $10 → $2
Current: $1.68
Upside: +19.05%
Zenas BioPharma
Mar 17, 2026
Reiterates: Buy
Price Target: $44
Current: $20.36
Upside: +116.11%
Immunic
Mar 2, 2026
Maintains: Buy
Price Target: $8 → $5
Current: $1.15
Upside: +334.78%
FibroBiologics
Feb 26, 2026
Maintains: Buy
Price Target: $100 → $80
Current: $1.33
Upside: +5,915.04%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $6.11
Upside: +194.60%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.41
Upside: +325.53%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $26.41
Upside: +112.04%
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.14
Upside: +133.39%
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $70.22
Upside: +25.32%
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $6.42
Upside: +86.92%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $9.35
Upside: +498.93%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $4.69
Upside: +70.58%
May 19, 2025
Reiterates: Neutral
Price Target: $9
Current: $9.60
Upside: -6.25%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $534.98
Upside: -94.77%